4月29日,中国国家药监局药品审评中心(CDE)官网最新公示,诺诚健华申报的1类新药ICP-248片拟纳入突破性治疗品种,用于既往接受过免疫化疗和布鲁顿氏酪氨酸激酶抑制剂(BTKi)治疗的复发/难治性套细胞淋巴瘤(r/r MCL)患者。公开资料显示,这是诺诚健华研发的BCL2抑制剂。截图来源:CDE官网ICP-248(mesutoclax)是一款新型口服高选择性BCL2抑制剂。BCL2是细胞凋亡...
Source Link4月29日,中国国家药监局药品审评中心(CDE)官网最新公示,诺诚健华申报的1类新药ICP-248片拟纳入突破性治疗品种,用于既往接受过免疫化疗和布鲁顿氏酪氨酸激酶抑制剂(BTKi)治疗的复发/难治性套细胞淋巴瘤(r/r MCL)患者。公开资料显示,这是诺诚健华研发的BCL2抑制剂。截图来源:CDE官网ICP-248(mesutoclax)是一款新型口服高选择性BCL2抑制剂。BCL2是细胞凋亡...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.